Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Sep 9 - Sep 14
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimers disease
Key findings include: Mean weight loss of 24.2% (approximately 58 pounds or 26.2 kg) with 12 mg weekly dose after 48 weeks Dose-dependent efficacy across 1 mg, 4 mg, 8 mg, and 12 mg dose groups At 48 weeks, 100% of participants receiving 8 mg or 12 mg achieved at least 5% weight loss 93% of participants on 12 mg achieved 15% or more weight loss , far exceeding current therapeutic benchmarks Greater weight reduction observed in participants with BMI greater than or equal to 35 compared to those with BMI below 35 The magnitude of weight loss approaches that typically observed only with bariatric-metabolic surgery, representing a potential paradigm shift in pharmacological obesity treatment[11]
This is why the weight loss is more substantial and sustained than most prior pharmacological approaches
Amini MR, Aminianfar A, Naghshi S, Larijani B, Esmaillzadeh A
US$ 29.33
US$ 25.96
US$ 24.00
US$ 25.54
